Literature DB >> 29578155

Meta-analysis of prognostic value of inflammation parameter in breast cancer.

Jie Chen1, Yuqin Pan2, Bangshun He2, Houqun Ying3, Huiling Sun1, Qiwen Deng2, Xian Liu2, Shukui Wang2.   

Abstract

CONTEXT: Recently, increasing studies investigated the association between inflammation parameter such as neutrophil to lymphocyte ratio (NLR) and the prognosis of cancers. However, the clinical and prognostic significance of NLR in breast cancer remains controversial. AIM: This meta-analysis was conducted to establish the overall accuracy of the NLR test in the diagnosis of breast cancer.
MATERIALS AND METHODS: A comprehensive search of the literature was conducted using PubMed and Web of Science. Six studies dating up to July 2014 with 2267 patients were enrolled in the present study. STATA 11.0 software (STATA Corporation, College Station, TX, USA) was selected for data analysis. In order to evaluate the association between NLR and overall survival (OS), disease-free survival (DFS), recurrence-free survival or cancer-specific survival, the hazard ratios (HRs), and their 95% confidence intervals (CIs) were extracted.
RESULTS: Subgroup analyses showed that NLR was a strong prognostic factor for OS in multivariate analysis (HR = 2.81, 95% CI = 2.13-3.71, PH = 0.992) and without metastasis (HR = 1.45, 95% CI = 0.37-5.66, PH < 0.001). Elevated NLR was associated with a high risk for DFS in subgroups of multivariate analysis (HR = 2.16, 95% CI = 1.67-2.80, PH = 0.977) and mixed metastasis (HR = 2.13, 95% CI = 1.38-3.30, PH = 0.84).
CONCLUSION: In summary, NLR may be considered as a predictive factor for patients with breast cancer.

Entities:  

Keywords:  Breast cancer; inflammation parameter; prognosis

Mesh:

Year:  2018        PMID: 29578155     DOI: 10.4103/0973-1482.160917

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients.

Authors:  B Losada; J A Guerra; D Malón; C Jara; L Rodriguez; S Del Barco
Journal:  Clin Transl Oncol       Date:  2018-11-30       Impact factor: 3.405

2.  Controlling Nutritional Status (CONUT) score is a prognostic factor in patients with resected breast cancer.

Authors:  Wen Li; Min Li; Ting Wang; Guangzhi Ma; Yunfu Deng; Dan Pu; Zhenkun Liu; Qiang Wu; Xuejuan Liu; Qinghua Zhou
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

3.  Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.

Authors:  Li Chen; Xiangyi Kong; Zhongzhao Wang; Xiangyu Wang; Yi Fang; Jing Wang
Journal:  J Cell Mol Med       Date:  2020-01-27       Impact factor: 5.310

4.  Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.

Authors:  Masayuki Shirasawa; Tatsuya Yoshida; Hidehito Horinouchi; Shigehisa Kitano; Sayaka Arakawa; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Shintaro Kanda; Reiko Watanabe; Noboru Yamamoto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Journal:  Br J Cancer       Date:  2020-11-30       Impact factor: 7.640

5.  Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.

Authors:  Li Chen; Xiangyi Kong; Zhongzhao Wang; Xiangyu Wang; Yi Fang; Jing Wang
Journal:  Cancer Manag Res       Date:  2020-03-03       Impact factor: 3.989

6.  Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Authors:  Meghan A Cupp; Margarita Cariolou; Ioanna Tzoulaki; Dagfinn Aune; Evangelos Evangelou; Antonio J Berlanga-Taylor
Journal:  BMC Med       Date:  2020-11-20       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.